Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects
Authors:
- 11 June 2007
- journal article
- Published by Hindawi Limited in European Journal of Cancer Care
- Vol. 16 (4) , 351-354
Abstract
Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects. Ondansetron and later members of the ’setron class are currently standard treatments for cancer chemotherapy-related nausea and emesis. They are potent 5-HT3 blockers, but it is often not appreciated that mirtazapine and olanzapine bind with similar affinity to 5-HT3 receptors, have a longer half-life, are considerably cheaper than the ’setron class, and often offer better and smoother 24-h nausea control than’setron class drugs. Mirtazapine and olanzapine often have salutary antianxiety effects and improve sleep quality. They occasionally relieve chemotherapy-related and advanced cancer-related nausea and appetite decrease better than the ’setron group that are specifically marketed for nausea control. Mirtazapine and olanzapine frequently give potent nausea reduction and appetite increase in advanced cancer-related cachexia. Several cytokine changes potentially induced by mirtazapine and olanzapine use are discussed that may have salutary effects in several cancers. We suggest mirtazapine and olanzapine be included as first-line options in treating both chemotherapy- and advanced cancer-related nausea. Multiple clinical and economic advantages of mirtazapine and olanzapine over currently used’setron class medicines are reviewed. Double-blind studies against the ’setron class drugs are warranted.Keywords
This publication has 20 references indexed in Scilit:
- Current Drugs Available Now for Interleukin-6 Suppression as Treatment Adjunct in Glioblastoma: Anakinra, Aprepitant, Mirtazapine and OlanzapineInternational Journal of Cancer Research, 2006
- Interleukin-6 regulation of prostate cancer cell growthJournal of Cellular Biochemistry, 2005
- Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomitingNature Clinical Practice Oncology, 2005
- TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-SignalingImmunity, 2004
- Spectrum of use and tolerability of 5‐HT3receptor antagonistsScandinavian Journal of Rheumatology, 2004
- Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myelomaMedical Hypotheses, 2004
- Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric DisordersNeuropsychopharmacology, 2002
- A Review of the Pharmacological and Clinical Profile of MirtazapineCNS Drug Reviews, 2001
- Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapySupportive Care in Cancer, 2001
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996